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Abstract
Background: International tourism increased from 25 million tourist arrivals in 1950 to over 1.3 billion in 2017.
These travelers can be exposed to (multi) resistant microorganisms, may become colonized, and bring them back
home. This systematic review aims to identify the carriage rates of multidrug-resistant Enterobacterales (MDR-E)
among returning travelers, to identify microbiological methods used, and to identify the leading risk factors for
acquiring MDR-E during international travel.
Methods: Articles related to our research question were identified through a literature search in multiple databases
(until June 18, 2019) - Embase, Medline Ovid, Cochrane, Scopus, Cinahl, Web of Science, and Google Scholar.
Results: Out of 3211 potentially relevant articles, we included 22 studies in the systematic review, and 12 studies in
7 random-effects meta-analyses. Highest carriage rates of MDR-E were observed after travel to Southern Asia
(median 71%), followed by travel to Northern Africa (median 42%). Carbapenemase-producing Enterobacterales
(CPE) were identified in 5 out of 22 studies, from a few patients. However, in only eight out of 22 studies (36.4%)
the initial laboratory method targeted detection of the presence of CPE in the original samples. The risk factor with
the highest pooled odds ratio (OR) for MDR-E was travel to Southern Asia (pooled OR = 14.16, 95% confidence
interval [CI] = 5.50 to 36.45), followed by antibiotic use during travel (pooled OR = 2.78, 95% CI = 1.76 to 4.39).
Conclusions: Risk of acquiring MDR-E while travelling increases depending on travel destination and if antibiotics
are used during travel. This information is useful for the development of guidelines for healthcare facilities with low
MDR-E prevalence rates to prevent admission of carriers without appropriate measures. The impact of such
guidelines should be assessed.
Keywords: Travel, Enterobacteriaceae, Enterobacterales, Systematic review, Meta-analysis, Antimicrobial resistance,
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Introduction
Multidrug resistance, defined as acquired non-
susceptibility to at least one agent in three or more anti-
microbial categories, of clinically important bacteria is
recognized as a major threat for human health world-
wide. However, remarkable geographical differences in
prevalence and trends exist [1, 2]. Multidrug-resistant
(MDR) Enterobacterales (MDR-E) that produce
extended-spectrum beta-lactamases (ESBL) and/or car-
bapenemases are of most concern, since these bacteria
are able to colonize the human gut and may cause a var-
iety of infections that subsequently require more compli-
cated treatments [3, 4]. Fecal colonization rates with
ESBL-producing Enterobacterales (ESBL-E) are esti-
mated to be 14% among healthy individuals worldwide,
with an annual increase from 1990 to 2015 of around
5% [5]. These rates are higher in the Mediterranean, the
West Pacific, Africa and South-East Asia, and lower in
Northern Europe and North America [5]. The carriage
rate of carbapenemase-producing Enterobacterales
(CPE) in healthy individuals is estimated to be low or
absent, although only few studies have included healthy
people in a community setting. In East-London, 200
community stool samples were screened and no CPE
was identified [6]. CPE are mostly seen in people with
exposure to healthcare [7]. In some countries, however,
CPE are widespread in the environment [8, 9].
When people travel from low-prevalence areas to areas
with a higher prevalence of ESBL-E or CPE in the com-
munity, such strains may become part of their gut flora
and then carried to the travelers’ home country. This
risk is on the rise, since international tourism has in-
creased from 25 million tourist arrivals in 1950, to 1326
million tourist arrivals in 2017 with an expected annual
growth of 3.3% [10, 11]. This means that by 2030, 1.8
billion tourist arrivals will be reported. Additionally, be-
tween 2015 and 2016, travel to Oceania, Africa and
South-East Asia increased the most, by 9.4, 8.1 and 7.8%
respectively [10].
Tängdén et al. first reported on travel and acquisition
of ESBL-E in 2010 [12]. Since then, numerous reports
and several systematic reviews have been published on
the relationship between fecal colonization with MDR-E
and international travel [13, 14]. However, for healthcare
settings, especially those with a low prevalence of MDR-
E, it is still unclear how to translate this knowledge into
policies or guidelines for infection control and patient
care. In addition, it is unclear how travel clinics or gen-
eral practitioners can use the existing information for
pre-travel advice. This review adds to the existing litera-
ture by performing an extensive systematic review to de-
scribe carriage rates of MDR-E among returning
travelers, to describe microbiological methods used, and
to perform a meta-analysis in order to identify the
leading risk factors for acquiring MDR-E during inter-
national travel.
Methods
This systematic review and meta-analyses followed the
guidelines presented in the PRISMA statement (see
Additional file 1) [15]. Moreover, this study is an update
and extension of the study published by Hassing et al.
(Prospero registration number CRD42015024973),
whose database search was conducted on August 17,
2015 [16].
Study selection
Articles related to our research question were identified
through a literature search in multiple databases (until
June 18, 2019) ─ Embase, Medline Ovid, Cochrane,
Scopus, Cinahl, Web of Science, and Google Scholar
(see Additional file 2). The search was not limited by
language, date of publication, country of publication or
study design.
We used the following inclusion criteria during the
study selection: (i) related to foreign travel, (ii) reports
on systematic and selective screening for the carriage of
ESBL-E and/or CPE among travelers without signs of in-
fections when performing the screening, and (iii) report
on fecal Enterobacterales carriage. We excluded studies
related to nonhuman infections, hospital studies, studies
about symptomatic patients (e.g., travelers’ diarrhea
[TD]), conference abstracts, letters to the editor, com-
mentaries, weekly reports, and editorials. First, titles and
abstracts of all retrieved citations were screened inde-
pendently by KM and AFV. After this screening, KM,
AFV and BB performed a second screening based on the
full-text. Disagreements were resolved by discussion.
Reference lists of reviews and systematic reviews on the
same subject, which were identified during the literature
search, were screened to identify additional studies that
had been missed by our search strategy.
Data extraction
We designed a data extraction form and pilot-tested it
on two randomly selected articles, and redefined it ac-
cording to the outcomes. The following data were ex-
tracted by AFV and BB: first author, journal, year
published, country, study design, study period, where
were the participants recruited (e.g. travel agency, vac-
cination clinic), total number of participants, mean age,
percentage female, mean duration of travel, sample
method, microorganism(s) studied, co-travelers or
household members included, percentage of carriage be-
fore and after travel, acquisition rate, acquisition rate to
household members, acquisition rates for each United
Nations geographical region, laboratory methods (e.g.
species determination, phenotypic approaches, molecular
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approaches), risk factors and protective factors identified
in multivariable models; and corresponding odds ratio,
95% confidence interval and P-value. The completed
data extraction form was sent to the corresponding au-
thor of the original manuscript to verify the extracted
data, and to gain additional information if relevant. In
case we did not receive any response after the given
deadline (i.e. 2 weeks), a reminder was sent. If no re-
sponse was received and crucial information was miss-
ing, the study was excluded.
Data analysis
Carriage rates of multidrug-resistant Enterobacterales by
travel destination
The following geographical classification was used, based
on the United Nations geographical regions: (i) Southern
Asia, (ii) Asia except Southern Asia, (iii) Northern Af-
rica, (iv) Sub-Saharan Africa, (v) South and Central
America, (vi) North America, (vii) Europe, (viii) Oceania
(see Additional file 3). Carriage rates immediately after
return were grouped into the following 5 categories, and
for a visual presentation of the results a color was added
from green to dark red: (i) 0–20%, low, green; (ii) 21–
40%, moderate, yellow; (iii) 41–60%, high, orange; (iv)
61–80%, very high, red; (v) 81–100%, extremely high,
dark red.
Meta-analysis
All risk factors extracted from the articles for which an
odds ratio (OR) with 95% confidence interval (95%CI)
was reported were grouped into eight categories: (i) diar-
rhea during travel, (ii) antibiotic use during travel, (iii)
travel to Southern Asia, (iv) behavior during travel, (v)
food consumption during travel, (vi) length of stay, (vii)
sex, and (viii) age.
The meta-analyses for each category were performed
using StatsDirect statistical software (Altrincham, United
Kingdom) including the random-effects model of DerSi-
monian and Laird [17]. We used a random-effects model
to limit the influence of heterogeneity. A P-value of <
0.05 was considered statistically significant. Publication
bias was examined visually with use of funnel plots, and
assessed with the Egger and Begg-Mazumdar indicators
[18, 19].
Study quality
The methodological quality was assessed for all included
studies using the strengthening the reporting of observa-
tional studies in epidemiology (STROBE) guideline [20].
Studies with a score ≤ 15 out of 33 points were consid-
ered to be of relatively low methodological quality, stud-
ies receiving a quality score of 16–19 points were
considered as of moderate quality, and studies with ≥20
points were considered to have a relatively high study
quality. Study quality was not considered an exclusion
criterion.
Results
The literature search identified 3211 non-duplicate arti-
cles, of which 811 articles were potentially relevant for
this current study (Fig. 1). Titles and abstracts of these
811 articles were screened, which resulted in the exclu-
sion of 795 articles (98%). One additional study was in-
cluded after searching the reference lists of reviews of
interest. The remaining 17 articles underwent a second
screening based on the full-text, after which 6 articles
were excluded (35.3%) (Fig. 1). The remaining 11 studies
were added to the 11 previously identified by Hassing
et al., and used in his review. Hence, in total 22 articles
were included in this systematic review [16]. Of the 22
included articles, 12 were included in random-effects
meta-analyses (Fig. 1).
For the 22 included studies, the corresponding author
was contacted to provide feedback on extracted data or
to request additional information. The corresponding
authors of all studies (100%) responded to our request
to provide feedback on the extracted data. For three
studies, we requested additional information on the mul-
tivariable analysis since crucial information was missing.
Unfortunately, additional information was not received
and these studies were therefore excluded from the
random-effects meta-analyses.
Study characteristics
All 22 included studies were prospective cohort stud-
ies. The studies were conducted in Western Europe
(n = 17, 77.3%), North America (n = 2, 9.1%), Japan
(n = 2, 9.1%), and Australia (n = 1, 4.5%). The charac-
teristics of the studies are shown in Table 1. Fifteen
studies investigated travelers visiting a travel or vac-
cination clinic, one study investigated hospital staff
and contacts, one study investigated healthcare stu-
dents, one study investigated business travelers, one
study investigated Hajj pilgrims, and two studies did
not state the type of study population. The studies by
van Hattem et al. and Arcilla et al. both investigated
participants enrolled in the COMBAT-study (Clinical-
Trials.gov identifier: NCT01676974); van Hattem et al.
reported on CPE acquisition, and Arcilla et al. on
ESBL-E acquisition [36, 37].
The median study size was 160 participants, ranging
from 18 to 2001 participants, and the median age of par-
ticipants ranged from 25 years to 66 years, with partici-
pants included from 0 to 84 years old. The median
proportion of women was 61%, ranging from 26 to 78%;
one study did not report the gender of the participants.
Most studies had participants with a similar median dur-
ation of travel, ranging from median 14 to 21 days.
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However, the study investigating healthcare students had
a median duration of travel of 45 days (13–365) [28] and
in the study investigating business travelers, participants
travelled for at least 6 months [33]. Sample collection in
the included studies was via stool sample (n = 14,
63.6%), rectal swab (n = 6, 27.3%), a rectal swab or a
stool sample (n = 1, 4.5%), or a rectal or perianal swab
(n = 1, 4.5%). Four studies also investigated co-travelers
in addition to the study population [12, 29, 36, 37].
Three studies did not report on identification of micro-
organisms, and one study investigated a variety of
antimicrobial-resistant bacteria: ESBL-E, CPE and
colistin-resistant Gram-negative bacteria. Between the
latter two groups, Enterobacter cloacae and Escherichia
coli were the most frequently identified Enterobacterales,
respectively. In all other studies, ESBL-positive E. coli
was the most dominant MDR-E identified in post-travel
samples.
Only one study clearly defined TD as more than 3
loose/liquid stools per 24 h or more frequently than nor-
mal for an individual [29] and one study referred to the
World Health Organization (WHO) definition [42]. The
other included studies just asked in questionnaires if the
participant had experienced TD yes or no.
Microbiological methods
Enrichment was used in 12 out of 22 included studies
(54.5%), all with a different composition, and 21 out of
22 included studies (95.5%) used selective agar plates,
with 13 studies using ChromID ESBL (Table 2). The
method most often used for antimicrobial susceptibility
testing was the VITEK2 system (bioMérieux, 10 out of
22, 45.5%), and phenotypic confirmation of ESBL-
production was most often performed by disk-diffusion
(12 out of 22, 54.5%) (Table 2).
Fig. 1 Flow diagram of study selection
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Table 1 Study characteristics of the 22 included studies
Study Year Country Study
period
Population
characteristic
Study
sizea
Proportion of
MDR E. colie in
post-travel
isolates
Sample time (range)
before/after travel
Median
duration of
travel in days
(range)
Follow-up
of carriage
Kennedy [21] 2010 Australia January
2008–April
2009
Hospital staff
and contacts
102 > 92% E. colib Within 2 weeks before
and after
21 (9–135) 6 months
Tängdén [12] 2010 Sweden November
2007–
January
2009
Travel clinic 100 100% E. coli (24/
24b)
Unknown 14 (7–182) 6 months
Weisenberg
[22]
2012 United
States
July 2009–
February
2010
Travel clinic 28 E. coli 100% (7/
7b)
1 week before/within 1
week after
14 (8–42) None
Östholm-
Balkhed* [23,
24]
2013 Sweden September
2008–April
2009
Vaccination
clinic
231 90% E. coli (104/
116)b
15 (1–114) days/ 3 (0–
191) days
16 (4–119) 12 months
Paltansing* [25] 2013 The
Netherlands
March
2011–
September
2011
Travel clinic 370 92% E. coli (146/
158)c
Immediately before and
after
21 (6–90) 6 months
Kuenzli* [26] 2014 Switzerland December
2012–
October
2013
Travel clinic 190 98% E. coli (157/
161b)
Week before/directly after Mean; 18 (5–
35)
None
von
Wintersdorff
[27]
2014 The
Netherlands
November
2010–
August
2012
Travel clinic 122 ND Before and immediately
after
21 (5–240) None
Angelin* [28] 2015 Sweden April 2010–
January
2014
Healthcare
students
99 100% E. coli (35/
35c)
Close to departure/ 1–2
weeks after return
45 (13–365) None
Kantele* [29] 2015 Finland March
2009–
February
2010
Travel clinic 430 97% E. coli (94/
97b)
Before/first (or second)
stool after
Mean; 19 (4–
133)
12 months
Lübbert [30] 2015 Germany May 2013–
April 2014
Travel clinic 205 92% E. coli (58/
63b)
Before/within 1 week after 21 (2–218) 6 months
Ruppé* [31] 2015 France February
2012–April
2013
Vaccination
centers
574 93% E. coli (491/
526b)
Within 1 week before and
after
20 (IQR 15–
30)
12 months
Bernasconi [32] 2016 Switzerland January
2015–
August
2015
Unknown 38 90% E. coli (26/
29b)
Within 1 week before and
after
Mean; 15 (8–
35)
6 months
Mizuno [33] 2016 Japan September
2012–
March
2015
Business
travelers
57 ND Before and at time of
return
> 6months None
Reuland* [34] 2016 The
Netherlands
April 2012–
April 2013
Vaccination
clinic
445 97% E. coli (95/
98b)
Before/within 2 weeks
after
Mean; 14 (1–
105)
None
Vading* [35] 2016 Sweden April 2013–
May 2015
Travel clinic 188 97% E. coli (65/
67b)
Unknown 14 (IQR 8–20) 10 to 26
months
van Hattemd
[36]
2016 The
Netherlands
November
2012–
November
2013
Travel clinic 2001 60% E. coli (3/5b) Before/immediately and
1month after travel
20 (IQR 15–
25)
12 months
Arcilla*d [37] 2017 The
Netherlands
November
2012–
November
Travel clinic 2001 88% E. coli (759/
859b)
Before/immediately and
1month after travel
20 (IQR 15–
25)
12 months
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In eight out of 22 studies (36.4%) the initial laboratory
method targeted detection of the presence of CPE in the
original samples, i.e. a selective agar plate method with-
out a pre-enrichment with a broth containing second or
third generation cephalosporins (Table 2) [26, 29–31, 35,
36, 39, 42]. In only 4 of these eight studies, a CPE was
found [26, 31, 36, 42]. In 13 out of the 22 studies
(59.1%), screening for CPE was carried out in isolates or
directly on the specimen by a variety of phenotypic and
genotypic methods (Table 2). In other studies, carba-
penem susceptibility testing was partly or not performed,
or isolates with reduced susceptibility to carbapenems
were not further analyzed. Therefore, in those studies
CPE could have remained unidentified.
Carriage of multidrug-resistant Enterobacterales
International travelers
Table 3 shows the rates of travelers acquiring CPE, or
MDR-E (i.e. without CPE) during international travel. It
was not possible to report ESBL-E separate from MDR-
E, since multiple studies, when reporting prevalence
rates, combined ESBL-E and for example AmpC-
producing Enterobacterales. Highest carriage rates of
MDR-E were observed after travel to Southern Asia
(Table 3), with proportions ranging from 29 to 88%, with
as median 71%. Second was travel to Northern Africa,
with proportions ranging from 31 to 100%, with as me-
dian 42%. CPE carriage was only identified in 5 studies
[26, 31, 34, 36, 42], and mainly found in E. coli. Carbape-
nemases identified were IMI-2, NDM, NDM-1, NDM-1/
2, NDM-7, OXA-48, OXA-181 and OXA-244.
Household members
Acquisition of MDR-E from the traveler to a non-
travelling household member was described by 3 studies
[25, 36, 37]. In the study by Paltansing et al., 1 out of 11
(9.1%) household members carried the same ESBL-
producing E. coli as the traveler [25]. In the study by
Arcilla et al., 13 out of 168 (7.7%) household members
carried a microorganism with the same ESBL group as
the traveler [37]. When the authors estimated the trans-
mission rate after introduction into a household using a
Markov model, the probability of transmission was 12%
(95% CI = 5 to 18%) [37]. In the study by van Hattem
et al., acquisition of a blaOXA-244-positive E. coli from a
traveler to a household member was highly suspected.
Three months after travel a blaOXA-244-positive E. coli
with a similar AFLP pattern was isolated from a fecal
sample from a spouse and travel companion. All other
fecal specimens from this household member were CPE
negative, which suggested post-travel acquisition of the
same bacterium [36].
Persistence of colonization and subsequent infections
Fourteen studies performed follow-up analysis of persist-
ence of MDR-E colonization [12, 21, 24, 25, 29–32, 35–
Table 1 Study characteristics of the 22 included studies (Continued)
Study Year Country Study
period
Population
characteristic
Study
sizea
Proportion of
MDR E. colie in
post-travel
isolates
Sample time (range)
before/after travel
Median
duration of
travel in days
(range)
Follow-up
of carriage
2013
Leangapichart*
[38]
2017 France Hajj 2013 &
2014
Hajj pilgrims 218 ND Just before departure and
after the Hajj just before
return
22 and 24 None
Peirano* [39] 2017 Canada January
2012–July
2014
Travel clinic 116 100% E. coli
(124/124b)
Before /within 1 week
after
10–38 6 months
Bevan [40] 2018 United
Kingdom
March
2015–June
2016
University
and
university
hospital
18 100% E. coli (16/
16)
As close to the time of
sample submission and
after
21, mean 27 Up to 12
months
Nakayama [41] 2018 Japan June 2015–
August
2016
Unknown 19 100% E. coli Before and up to 2 weeks
after
2–12 days None
Schaumburg*
[42]
2019 Germany/
the
Netherlands
October
2016–
March
2018
Vaccination
center
132 ESBL-producing
Enterobacterales
Up to 1 week before
departure, during travel
and up to 1 week after
return
Mean: 18.7,
maximum of
six weeks
6 months
(137–420
days after
return)
Abbreviations: E. coli, Escherichia coli; MDR Multidrug-resistant; ND No data; *, included in the meta-analyses
a Number of travelers who provided pre-travel and post-travel samples
b MDR microorganisms newly acquired during travel
c Data about post-travel samples
d Reported on the same study population, however, van Hattem et al. reported on CPE acquisition, and Arcilla et al. on ESBL-E acquisition
e Including ESBL-producing E. coli and carbapenemase-producing E. coli
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Table 2 Microbiological methods of the 22 included studies
Study Enrichment Selective media AST Confirmation of
ESBL
CPE-
targeted
isolation
method
CPE screening in
isolates
Kennedy [21] Yes BHI broth with
vancomycin
disk
Yes MacConkey with NAL disk, horse BA
with gentamicin, ChromID ESBL
VITEK2 Disk-diffusion,
PCR for blaTEM,
blaSHV, and
blaCTX-M
No No
Tängdén [12] Yes LB broth with
cefotaxime
Yes MacConkey with cefotaxime and
ceftazidime disks
E-test Disk-diffusion No No, only carbapenem
AST
Weisenberg
[22]
No NA Yes MacConkey with cefpodoxime VITEK2 Disk-diffusion,
PCR for blaTEM,
blaSHV, and
blaCTX-M
No Yes, PCR for blaKPC,
blaIMP, blaVIM,
blaOXA-48, blaNDM
Östholm-
Balkhed [23]
No NA Yes ChromID ESBL, chromogenic UTI
agar with antibiotic disks
E-test E-test, PCR for
blaTEM, blaSHV,
and blaCTX-M
No No, only carbapenem
AST
Paltansing [25] Yes TSB with
cefotaxime
and
vancomycin
Yes ChromID ESBL VITEK2 Disk-diffusion,
microarray for
blaTEM, blaSHV,
and blaCTX-M
No Yes, microarray to
detect blaKPC, blaIMP,
blaVIM, blaOXA-48,
blaNDM-1
Kuenzli [26] Yes TSB with 0.5%
sodium
chloride
Yes ChromID ESBL, MacConkey with
ertapenem disk
VITEK2 Disk-diffusion,
selection of
isolates:
microarray for
blaTEM, blaSHV,
and blaCTX-M
Yes Yes, modified Hodge,
selection of isolates:
microarray for blaKPC,
blaIMP, blaVIM,
blaOXA-48, blaNDM
von
Wintersdorff
[27]
NA NA NA NA NA PCR for blaCTX-M No Yes, PCR for blaNDM
Angelin [28] No NA Yes ChromID ESBL Disk-
diffusion
E-test No Yes, disk-diffusion for
blaOXA-48 and
blaOXA-181 and
CT103XL microarray
Kantele [29] No NA Yes ESBL, KPC (CHROMagar) VITEK2 Disk-diffusion Yes No, only AST
Lübbert [30] No NA Yes CHROMagar ESBL, CHROMagar KPC
plate
Microbroth
dilution
E-test, PCR for
blaTEM, blaSHV,
and blaCTX-M
Yes Yes, multiplex PCR for
blaKPC, blaIMP, blaVIM,
blaOXA-48, blaNDM
Ruppé [31] Yes (1) BHI broth
with
cefotaxime; (2)
BHI broth with
ertapenem
Yes (1) With and without enrichment:
ChromID ESBL agar; without
enrichment: bi-valve ESBL agar; (2)
Drigalski agar with ertapenem and
imipenem E-test
Disk-
diffusion
PCR for blaTEM,
blaSHV, blaCTX-M,
and blaVEB
Yes Yes, PCR for blaKPC,
blaIMP, blaVIM,
blaOXA-48, blaNDM
Bernasconi
[32]
Yes LB broth with
a cefuroxime
disk
Yes BLSE, ChromID ESBL, Supercarba
selective plates
Microdilution CT103XL
microarray
No Yes, CT103XL
microarray
Mizuno [33] No NA Yes ChromID ESBL MicroScan
Neg Combo
6.11 J panel
Disk-diffusion No No, only imipenem
AST
Reuland [34] Yes TSB with
ampicillin
Yes EbSA ESBL agar, CLED agar with
ciprofloxacin disk
VITEK2 Disk-diffusion,
PCR for ESBL
genes
No Yes, ertapenem E-test,
PCR for carbapene-
mase genes followed
by sequencing
Vading [35] Yes LB broth with
meropenem
Yes In-house chromogenic base with
cloxacillin and meropenem; without
enrichment: ChromID ESBL
Disk-
diffusion
Vitek2, Check-
MDR microarray
Yes Yes, Check-MDR
microarray
van Hattem
[36]
Yes TSB with
vancomycin
Yes ChromID ESBL, chromID OXA-48
agar
VITEK2, E-test Disk-diffusion,
Identibac® AMR08
microarray
Yes Yes, Identibac®
AMR08 microarray
and targeted PCR and
DNA sequencing
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37, 39, 40, 42], ranging from 6 to 26months (Table 1).
The median reported persistence rate of acquired MDR-E
at one, three, six and 12 months after return was 42.9,
22.4, 18.0 and 4.2% respectively. Arcilla et al. also reported
on the rate of intermittent carriage of acquired MDR-E,
which was 2.6% of all follow-up participants at 3 months,
3.0% at 6 months and 4.7% at 12 months [37]. Schaum-
burg et al. also calculated the median time of event-free
survival for ESBL-E (i.e. time to first colonization with
ESBL-E during travel), which was 8 days [42].
Five studies [12, 21, 30, 31, 35] investigated whether
the colonizing pathogen caused clinical infection after-
wards. Only a few clinical infections resulting from
colonization with MDR-E have been reported. The study
by Kennedy et al. reported one urinary tract infection
(UTI) out of 50 follow-up participants caused by an E.
coli with the same resistance pattern as the colonizing E.
coli [21]. Ruppé et al. reported that eight out of 245
follow-up participants had contracted a UTI during the
follow-up period, but no microbiological data was avail-
able to confirm that these infections were caused by the
colonizing pathogen [31]. Studies by Lübbert et al.,
Tängdén et al. and Vading et al. reported no clinical in-
fections in respectively 58, 21, and 56 follow-up partici-
pants [12, 30, 35].
Protective factors and risk factors
We identified 12 studies describing protective and/or
risk factors for acquiring MDR-E during travel, obtained
from multivariable analyses (see Additional file 4). The
highest OR was reported for the risk factor TD (OR =
31.00, 95% CI = 2.70 to 358.10). Examples of identified
protective factors were handwashing with soap before
meals, a beach holiday, tap water consumption, and
travel to various countries compared to traveling to Asia
(see Additional file 4).
All identified risk factors, protective factors, and fac-
tors identified as non-significant in multivariable models
were grouped into 8 categories. For these 8 categories, 7
meta-analyses were performed. For the category length
of stay, three factors were identified. However, for one
factor the confidence interval was missing. Therefore,
for the category length of stay no meta-analysis was per-
formed. The factor antibiotic use during travel was most
frequently described (n = 13 times identified).
The risk factor with highest pooled OR was found to
be travel to Southern Asia (pooled OR = 14.16, 95% CI =
5.50 to 36.45) (Fig. 2-c), followed by antibiotic use dur-
ing travel (pooled OR = 2.78, 95% CI = 1.76 to 4.39) (Fig.
2-b) and TD (pooled OR = 2.02, 95% CI = 1.45 to 2.81)
(Fig. 2-a). The factors behavior during travel (Fig. 2-d),
food consumption during travel (Fig. 2-e), male gender
(Fig. 2-f), and older age (Fig. 2-g) were identified as non-
significant factors. Publication bias indicators Begg-
Mazumdar (Kendall’s tau) and Egger both showed a sta-
tistically significant result in the following meta-analyses:
travel to Southern Asia, and older age (see Additional
file 5). Funnel plots are available in Additional file 5.
Table 2 Microbiological methods of the 22 included studies (Continued)
Study Enrichment Selective media AST Confirmation of
ESBL
CPE-
targeted
isolation
method
CPE screening in
isolates
Arcilla [37] Yes TSB with
vancomycin
Yes ChromID ESBL VITEK2 Disk-diffusion No No
Leangapichart
[38, 43, 44]
Yes TSB Yes MacConkey with cefotaxime and
Cepacia agar
Disk-
diffusion
PCR for blaTEM,
blaSHV, and
blaCTX-M
No No, only imipenem
AST
Peirano [39] No NA Yes ChromID ESBL, chromID-CARBA
SMART
VITEK2 Disk-diffusion,
PCR for blaTEM,
blaSHV, and
blaCTX-M
Yes Partly, carbapenem
AST, PCR for blaOXA
Bevan [40] Yes BHI broth with
cefpodoxime
disk
Yes Oxoid ESBL brilliance agar, Oxoid
UTI brilliance agar with
cefpodoxime disk
NP PCR for CTX-M
ESBL genes
No Yes, WGS and
bioinformatics
screening
Nakayama [41] No NA Yes CHROMagar ECC with 1 μg/mL
cefotaxime
Disk
diffusion
Double-disk
synergy test, PCR
for ESBL genes
No No, only meropenem
AST
Schaumburg
[42]
No NA Yes ChromID-ESBL, chromID-CARBA VITEK2 Double-disk
diffusion
Yes Yes, modified Hodge
test and PCR for
blaKPC2–15, blaVIM1–37,
blaNDM1–7, blaOXA-48,
blaOXA-181
Abbreviations: NAL Nalidixic acid; NA Not applicable; NR Not reported; AST Antimicrobial susceptibility testing; TSB Tryptic soy broth; ESBL Extended-spectrum beta-
lactamase; KPC Klebsiella pneumoniae carbapenemase; BA Blood agar; LB Luria-Bertani; BHI Brain heart infusion; CLED Cystine lactose electrolyte-deficient medium;
SMART Solutions to manage the antimicrobial resistance threat; NP Not performed; WGS Whole-genome sequencing
Voor in ‘t holt et al. Antimicrobial Resistance and Infection Control            (2020) 9:71 Page 8 of 14
Table 3 Proportion of travelers who acquired a resistant microorganism after international travel
Abbreviations: NR Not reported; CPE Carbapenemase-producing Enterobacterales; MDR-E Multidrug-resistant Enterobacterales
Colors: (i) 0–20%, low, green; (ii) 21–40%, moderate, yellow; (iii) 41–60%, high, orange; (iv) 61–80%, very high, red; (v) 81–100%, extremely high, dark red.
a Only noted for studies that used methods to be able to identify CPE as described in Table 2.
b Travelers who visited several regions are arranged to the region in which they spend the most time.
c Travelers who visited several regions are arranged to all of the visited regions.
d 42 travelers visited several countries in Asia and may therefore be arranged in several columns in the table; 28 of them acquired a MDR-E.
e Carriage rates after travel from travelers to Southern-Asia (CPE: 3 out of 17, ESBL: 13 out of 17), Asia except Southern Asia (CPE: 1 out of 29, ESBL: 17 out of 29),
Northern Africa (ESBL: 3 out of 3) and Sub-Saharan Africa (ESBL: 9 out of 27) were received from the corresponding author.
f Not including CPE. It was not possible to report ESBL-E separate from MDR-E.
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Study quality
A quality assessment was performed for all included
studies; n = 22. Overall, the studies scored between 9
and 26 out of 33 points, with a median of 18 points. Six
studies had a low methodological quality [22, 27, 28, 32,
33, 38, 41], seven a moderate methodological quality [12,
21, 23, 25, 26, 30, 36], and six studies a high methodo-
logical quality [29, 31, 34, 35, 37, 39, 40, 42].
Discussion
Summary of evidence
We identified that when travelling to Southern Asia (i.e.
Afghanistan, Bangladesh, Bhutan, India, Iran, Maldives,
Nepal, Pakistan and Sri Lanka) people are at highest risk
of acquiring and carrying a MDR-E upon return.
Though, acquisition of MDR-E when visiting Northern
Africa or Asia except Southern Asia was also high
(Table 3). Additionally, we showed that acquiring a CPE
while travelling is still rare, which is supported by the
findings of Jans et al. [45]. However, it should be empha-
sized that in most studies a culture method was used
that was not specifically targeting CPE. Especially CPE
with OXA-48-like carbapenemases may be missed [36].
The risk factors for acquiring MDR-E in order of those
with the highest to those with the lowest pooled OR are:
(i) travel to Southern Asia; (ii) antibiotic use during
travel; and (iii) TD. Older age, sex, food consumption
during travel and behavior during travel were found to
be non-significant (Fig. 2). With this systematic review,
we aimed to provide aggregated data on acquisition of
MDR-E and risk factors for MDR-E acquisition during
international travel, which can be useful for the develop-
ment of guidelines and policies in areas with a low
prevalence of MDR-E.
Travel to Asia, especially to India, is a known high risk
for acquiring MDR-E. MDR-E are highly prevalent in
this area because of the overuse of antibiotics, the lack
of (clean) toilets and the lack of clean water. Hereby,
bacteria can become resistant and are easily spread be-
tween people and to the environment. TD is associated
with contaminated food or water, and is related to the
lack of hygiene and sanitation [46]. Bacteria are respon-
sible for the majority of cases [46]. TD in combination
with antibiotic use does not only increase the risk of ac-
quiring MDR-E, but also selects for antibiotic resistant
Fig. 2 Forest plots of random-effects meta-analyses of risk factors for
acquiring multidrug-resistant Enterobacterales during international
travel (a to g appear from top to bottom). (a) Experienced diarrhea
while travelling (i.e. TD); (b) antibiotic use during travel; c) travelled
to Southern Asia; (d) behavior during travel (e.g. brought disposable
gloves, consumed bottled water); (e) food consumption during
travel (e.g. ice cream and pastry consumption, meals at street food
stalls); (f) male gender; (g) older age
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bacteria [46–49]. Our results in combination with the
studies by Kantele et al. highlight the need to avoid anti-
biotic use in mild to moderate TD [47–49]. Because
most diarrheal episodes are self-limiting, it is only im-
portant to avoid dehydration [46]. Additionally, only one
study used a clear definition of TD [29]. As described by
Lääveri et al., the impact of the definition of TD is sub-
stantial on the results and conclusions [50].
Interestingly, food consumption – a known risk factor
for TD and thus acquiring MDR-E – was identified as
non-significant. It may be that, because of all warnings
and available guides, people are aware of the risks and
stopped eating food from street vendors, raw food, and
stopped drinking tap water, milk from open containers
and fountain drinks [51]. Alternatively, it is also possible
that recall bias played a role in the questionnaires’ out-
comes, and food consumption was rarely identified as a
risk factor because people unknowingly eat risky food.
In our opinion, this is more likely, as it may be difficult
for travelers to determine if establishments adhere to
food safety standards [52, 53].
Towards a guideline
Although in our opinion the aggregated data do support
the implementation of additional recommendations that
can be given by travel clinics and general practitioners
to people before travelling, there are still a number of
knowledge gaps that need be filled before national and
international guidelines on infection control (screening
and/or isolation) and patient care (adjustment of empiric
treatment) for healthcare facilities can be developed.
First, the proportion of people with recent travel history
to a foreign country with increased risk of MDR-E ac-
quisition among patients admitted to hospitals is cur-
rently unknown. Second, it is unknown whether the
strains that are carried by travelers do spread in hospi-
tals, although it is known that in general ESBL-E and
CPE can be transmitted between patients and into the
hospital environment, especially when contact precau-
tions are not taken, which can lead to outbreaks [54].
The fact that not only strains, but also resistance genes
on mobile genetic elements such as plasmids can spread,
makes this knowledge gap even more difficult to resolve.
The cost-effectiveness of a program that would include
screening and subsequent isolation of recent travelers
can therefore not be estimated with the currently avail-
able data, nor can the overall impact of such a program
on healthcare workers, laboratories and patients. The
threshold of a carriage rate after travel that warrants
screening and/or isolation is also an unresolved issue,
but is likely to be dependent on the local carriage rates.
For example, when travelling to Sub-Saharan Africa,
17% of travelers acquire ESBL-E. For the Netherlands, a
country with a carriage rate in the community of 5.3 to
9.9%, 17% can be considered as high [54]. However, for
example in countries with higher community carriage
rates, other approaches may be more applicable. Such
policies would also require systematic surveillance of
carriage rates amongst travelers, or of local carriage
rates. The burden of disease of travel-related MDR-E is
also unknown. Follow-up data on infections in travelers
is scarce, as is data on phylogenetic groups (PG) of E.
coli and virulence factors in general. The limited avail-
able data suggest that infections are rare, clones may be-
long to low-virulent sequence types, and the PG varies
between studies [12, 25, 26, 30, 35, 40, 55]. Third, most
studies were performed in Europe and included travelers
who visited a travel clinic. Therefore, just a few studies
included travelers who visited Europe. In addition, few
travelers to North America or Oceania were included in
the studies in this review, possibly due to travelers not
seeing a travel clinic when visiting these continents.
Travelers visiting friends and relatives abroad are also
underrepresented, since they usually do not seek health
advice in a travel clinic before travelling. Additional
studies are needed to assess the risks of these groups of
travelers.
Strengths and limitations
A strength of our study is that it is an extensive litera-
ture search. In addition to the systematic review by Has-
sing et al., we performed meta-analyses to identify the
main risk factors, looked more into detail to the labora-
tory methods and subsequent possibility to identify CPE
and identified knowledge gaps. In addition, we per-
formed an in-depth analysis about carriage rates (e.g.
carriage rates of travelers, acquisition to household
members and persistence of carriage).
This study has some limitations. First, the heterogen-
eity of included studies. We included studies performed
in different countries and studying different types and
groups of travelers. Additionally, the prevalence of
MDR-E in each country is different and this was not in-
corporated in the risk factor analysis. To limit the influ-
ence of heterogeneity, in the meta-analysis we used a
random effects model. Second, publication bias was
present in several meta-analyses. Despite our extensive
search for all available evidence, small studies with no
effect are simply not performed and/or published. How-
ever, because of our extensive search, we think that the
influence of publication bias to our results and conclu-
sions is limited. Third, seven studies were included with
a low methodological quality, of which 2 were included
in the meta-analyses. These were relatively small studies,
which did not have a big influence in weight on the
pooled estimate. Therefore, we consider the influence of
studies with a low methodological quality as limited.
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Conclusion
This systematic review shows that travel to South Asia,
together with antibiotic use and TD, are leading risk fac-
tors for acquiring MDR-E. It is advisable for travelers to
contact a travel clinic in their home country before
travel to be informed about TD and antibiotic use, and
to limit self-prescribing of antibiotics and buying antibi-
otics over the counter during travel when suffering from
TD. Acquisition of CPE during travel is still rare, but
possibly underreported. The information in this review
is useful for the development of guidelines for healthcare
facilities with low MDR-E prevalence rates to prevent
admission of potential carriers of MDR-E without appro-
priate measures. However, we identified a number of
knowledge gaps that should be filled in before guidelines
for healthcare facilities can be developed and imple-
mented, since the impact of the measures cannot be esti-
mated yet.
COVID-19
Currently, we are in the midst of the COVID-19 pan-
demic. Governments are discouraging or forbidding
travel of any kind, and calling on everyone to stay at
home as much as possible. Additionally, several coun-
tries have implemented a full lockdown or shelter-in-
place measures. Healthcare systems are severely affected.
Furthermore, these measures have a significant impact
on domestic and international travel. This also affects
the spread of MDR-E: we expect a decreased transmis-
sion rate during this period due to the decrease in
(inter)national travel. However, an increased use of anti-
biotics has also been observed. We expect that this,
combined with overcrowding and a shortage of personal
protective equipment in hospitals, will lead to an in-
crease of local spread of MDR-E, and consequently, we
expect an increased local prevalence of MDR-E in low-
and-middle income countries and in Southern European
countries. If in the second half of 2020 international
travel is resumed due to relaxing of COVID-19 mea-
sures, we will see the results of this local spread. We ex-
pect that the proportion of travelers who acquire a
resistant microorganism after international travel will in-
crease after COVID-19. Future surveys will provide
more insight in the effect of the COVID-19 pandemic
on travel-related spread of MDR-E.
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